The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,780,276 in first-year total cost, median $569,842.
Most frequent study sections
- Neurological Sciences and Disorders A Study Section[NSD-A]4
- Neurological Sciences and Disorders B Study Section[NSD-B]1
Most frequent institutions
- ACORDA THERAPEUTICS, INC.1
- DUKE UNIVERSITY1
- TEXAS ENGINEERING EXPERIMENT STATION1
- UNIVERSITY HEALTH NETWORK1
- WASHINGTON UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2015 | Shape Memory Polymer Embolic Foams for Treating Cerebrovascular Aneurysms1U01NS089692-01 | MAITLAND, DUNCAN J | TEXAS ENGINEERING EXPERIMENT STATION, TX | $871,828 | NSD |
| 2015 | Human EGFRvIII-specific BiTE for the treatment of Glioblastoma1U01NS090284-01 | SAMPSON, JOHN H. | DUKE UNIVERSITY, NC | $569,842 | NSD |
| 2014 | Development of a next-generation PSD95 Inhibitor for the treatment of acute ische1U01NS087876-01 | TYMIANSKI, MICHAEL | UNIVERSITY HEALTH NETWORK, ON | $573,259 | NSD |
| 2014 | Translational Development of Glial Growth Factor 2 (GGF2) for the Treatment of St1U01NS076474-01A1 | CAGGIANO, ANTHONY OROSENE, DOUGLAS L | ACORDA THERAPEUTICS, INC., NY | $476,872 | NSD |
| 2014 | Development of an antisense oligonucleotide therapy for SOD1 Familial ALS1U01NS084970-01A1 | MILLER, TIMOTHY M. | WASHINGTON UNIVERSITY, MO | $288,475 | NSD |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.